Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation
Brief Summary: The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).


Options:
A: Inclusion Criteria:

* Clinical diagnosis of erectile dysfunction (ED), International Index of Erectile Function (IIEF) score \>=21 at screening and baseline, and receiving treatment with a stable regimen of a phosphodiesterase 5 (PDE 5) inhibitor (ie, sildenafil, vardenafil, or tadalafil) for the treatment of ED for at least 3 months before screening
* Study participant in a stable, monogamous sexual relationship with the same woman for at least 6 months before screening and plan to maintain this relationship for the duration of the study
* Study participant medically stable (ie, in good general health) on the basis of physical examination, medical history, vital signs, 12 lead ECG, and clinical laboratory tests performed at screening

Exclusion Criteria:

* History suggestive of syncope (a condition characterized by a loss of consciousness)
* History of medical events such as surgical interventions or neurologic conditions (eg, multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE
* Current major psychiatric disorder such as mood disorder, anxiety disorder, schizophrenia, mania, suicidal ideation, other psychotic disorder, or alcoholism
* Known allergy, hypersensitivity, or intolerance to selective serotonin reuptake inhibitors (SSRIs) or selective noradrenaline reuptake inhibitors (SNRIs)
* Taken another investigational drug (or vaccine) within 30 days or used an investigational medical device within 6 months before screening, or enrolled in another investigational study
B: Inclusion Criteria:

* Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study
* diagnosis of premature ejaculation (PE) according to the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) for at least 6 months before study initiation
* history of intravaginal ejaculatory latency time (IELT) of \<2 minutes in at least 3 out of 4 events
* good general health
* patient's partner must have a negative urine pregnancy test at time of screening

Exclusion Criteria:

* Not taken dapoxetine or participated in another study investigating pharmacologic treatment of PE within the last 3 months
* no history of any medical events that are associated with the development of PE
* not taken another investigational drug within 1 month, or used an experimental medical device within 6 months, of study initiation
* no positive diagnosis of depressive or anxiety disorder, manic episode, panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, alcohol abuse and dependence, schizophrenia, or other psychotic disorders
* no known allergy or hypersensitivity to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
C: Inclusion Criteria:

* Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study
* history of premature ejaculation in the 6 months before study initiation not due to distress, interpersonal difficulty or medication withdrawal
* history of intravaginal ejaculatory latency time (IELT) of \< = 2 minutes in at least 3 out of 4 events
* blood pressure \< = 180/100 mmHg at screening and end of baseline
* patient and partner must agree to attempt sexual intercourse at minimum intervals specified in the protocol
* patient's partner must have a negative urine pregnancy test at time of screening

Exclusion Criteria:

* Not taken dapoxetine in a previous investigational drug study
* not using other forms of therapy for treatment of PE (behavioral therapy or medications applied to the skin)
* no history of any medical events that are associated with the development of PE
* not taken another investigational drug within 1 month
* no history of seizures or major psychiatric disorder such as depression or schizophrenia
* no alcohol abuse and dependence
* no known allergy or hypersensitivity to dapoxetine or other selective serotonin reuptake inhibitors (SSRIs)
* no partners with decreased interest in or painful intercourse or other forms of sexual dysfunction
D: Inclusion Criteria:

* Heterosexual male in a stable, monogamous, sexual relationship with a female partner for at least 6 months
* onset of orgasm and ejaculation occurs with minimal sexual stimulation before or shortly after penetration and before the person wishes it
* premature ejaculation (PE) in the majority of intercourse experiences in the 6 months before study initiation
* intravaginal latency ejaculatory time (IELT) of \<=2 minutes in at least 3 out of 4 events
* participants with partners of child-bearing potential must consent to use a medically acceptable method of contraception throughout the entire study
* participant's partner must have a negative pregnancy test at time of screening.

Exclusion Criteria:

* History of surgery or injury to the pelvis or spinal cord, chronic inflammation of the prostate or urethra
* taking medications that are contraindicated for participation in the study
* currently using other forms of therapy for treatment of PE (for example, behavioral therapy or medications applied locally)
* previously participated in a drug study involving dapoxetine or in another drug trial within the last month
* taken pimozide, astemizole, or monoamine oxidase inhibitors within 6 months of the start of the study.

Answer: D